Evidence map›Paper›PMID 37554516›Full record

ArticleJID innovations : skin science from molecules to population health2023

Skin Infiltrate Composition as a Telling Measure of Responses to Checkpoint Inhibitors.

Cory Kosche, Dinesh Jaishankar, Cormac Cosgrove, Prathyaya Ramesh, Suyeon Hong, Lin Li, Rohan S Shivde, Deven Bhuva, Bethany E Perez White, Sabah S Munir and 4 more

Abstract read
In one paragraph

Article in JID innovations : skin science from molecules to population health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cory KoscheDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Dinesh JaishankarDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Cormac CosgroveDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Prathyaya RameshLurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Suyeon HongDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Lin LiDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Rohan S ShivdeLurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Deven BhuvaDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Bethany E Perez WhiteDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Sabah S MunirDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Hui ZhangDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Kurt Q LuDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Jennifer N ChoiDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
I Caroline Le PooleDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Funding

Translation & trials: advancing medical countermeasure developmentU54AR079795 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LU, KURT · 2021 to 2024
$10.9M
Northwestern University Skin Disease Research Center Resource-based CenterP30AR075049 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Irina Budunova · 2019 to 2026
$6.6M
Translation of novel and repurposed drugs to address the acute and late effects of mustard exposureU01AR071168 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LU, KURT · 2017 to 2021
$4.1M
Separating autoimmunity and anti-tumor immunityR01CA191317 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LE POOLE, I. CAROLINE · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA191317NIAMS NIH HHS P30 AR075049NIAMS NIH HHS U01 AR071168NIAMS NIH HHS U54 AR079795
6 · The paper itself

Abstract

Checkpoint inhibitors treat a variety of tumor types with significant benefits. Unfortunately, these therapies come with diverse adverse events. Skin rash is observed early into treatment and might serve as an indicator of downstream responses to therapy. We studied the cellular composition of cutaneous eruptions and whether their contribution varies with the treatment applied. Skin samples from 18 patients with cancer and 11 controls were evaluated by mono- and multiplex imaging, quantification, and statistical analysis. T cells were the prime contributors to skin rash, with T cells and macrophages interacting and proliferating on site. Among T cell subsets examined, type 1 and 17 T cells were relatively increased among inflammatory skin infiltrates. A combination of increased cytotoxic T cell content and decreased macrophage abundance was associated with dual checkpoint inhibition over PD1 inhibition alone. Importantly, responders significantly separated from nonresponders by greater CD68

Identifiers

PMID37554516
PMCPMC10405096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.